首页> 外文OA文献 >Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target
【2h】

Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target

机译:直肠癌放化疗后三叶因子3(TFF3)的上调是不良预后因素和潜在的治疗靶点

摘要

[Purpose]: Management of locally advanced rectal cancer (RC) consists of neoadjuvant chemoradiotherapy (CRT) with fluoropyrimidines, followed by total mesorectal excision. We sought to evaluate the expression of selected genes, some of which were derived from a previous undirected SAGE (serial analysis of gene expression)-based approach, before and after CRT, to identify mechanisms of resistance. [Methods]: This retrospective cohort study included 129 consecutive patients. Quantitative polymerase chain reaction of 53 candidate genes was performed on the biopsy specimen before treatment and on the surgical specimen after CRT. A paired-samples t test was performed to determine genes that were significantly changed after CRT. The result was correlated with patients' disease-free survival. [Results]: Twenty-two genes were significantly upregulated, and two were significantly downregulated. Several of the upregulated genes have roles in cell cycle control; these include CCNB1IP1, RCC1, EEF2, CDKN1, TFF3, and BCL2. The upregulation of TFF3 was associated with worse disease-free survival on multivariate analyses (hazard ratio, 2.64; P=.027). Patients whose surgical specimens immunohistochemically showed secretion of TFF3 into the lumen of the tumoral microglands had a higher risk of relapse (hazard ratio, 2.51; P=.014). In vitro experiments showed that DLD-1 cells stably transfected with TFF3 were significantly less sensitive to 5-fluorouracil and showed upregulation of genes involved in the transcriptional machinery and in resistance to apoptosis. [Conclusion]: Upregulation of TFF3 after CRT for RC is associated with a higher risk of relapse. The physiological role of TFF3 in restoring the mucosa during CRT could be interfering with treatment efficacy. Our results could reveal not only a novel RC prognostic marker but also a therapeutic target. © 2012 Elsevier Inc. All rights reserved.
机译:[目的]:局部晚期直肠癌(RC)的治疗包括用氟嘧啶类新辅助放化疗(CRT),然后进行全直肠系膜切除。我们试图评估选定的基因的表达,其中一些源自先前的无方向性SAGE(基因表达的序列分析)方法,在CRT之前和之后,以鉴定抗药性的机制。 [方法]:这项回顾性队列研究纳入了129位连续患者。在治疗前对活检标本和CRT后在手术标本上进行了53个候选基因的定量聚合酶链反应。进行配对样本t检验以确定CRT后显着改变的基因。结果与患者无病生存相关。 [结果]:22个基因显着上调,两个基因显着下调。一些上调的基因在细胞周期控制中起作用。这些包括CCNB1IP1,RCC1,EEF2,CDKN1,TFF3和BCL2。在多变量分析中,TFF3的上调与较差的无病生存率相关(危险比,2.64; P = .027)。手术标本免疫组织化学显示TFF3分泌到肿瘤微腺腔内的患者复发风险更高(危险比,2.51; P = .014)。体外实验表明,用TFF3稳定转染的DLD-1细胞对5-氟尿嘧啶的敏感性显着降低,并显示了转录机制和抗凋亡基因的上调。 [结论]:RC的CRT后TFF3的上调与较高的复发风险相关。 TFF3在CRT期间恢复黏膜的生理作用可能会干扰治疗效果。我们的结果不仅可以揭示新型的RC预后标志物,还可以揭示治疗目标。 ©2012 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号